查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1630991

溶小体酸性脂肪酶缺乏症治疗市场规模、份额、趋势分析报告：按适应症、按治疗方法、按地区、细分市场预测，2025-2030 年

Lysosomal Acid Lipase Deficiency Treatment Market Size, Share & Trends Analysis Report By Indication (Wolman Disease, Cholesteryl Ester Storage Disease), By Treatment, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

溶小体酸性脂肪酶缺乏症治疗市场的成长与趋势：

根据Grand View Research最新报告，到2030年，全球溶小体酸性脂肪酶缺乏症治疗市场规模预计将达到4.332亿美元，2025年至2030年复合年增长率为7.2%。大量未满足的需求、不断上升的盛行率以及酵素替代疗法的广泛采用是推动市场发展的一些关键因素。

LAL 缺乏症 (LAL-D) 是一种罕见的溶小体贮积症，患者由于 LAL 基因突变而无法分解胆固醇酯和三酸甘油酯。结果，脂质在肝臟、脾臟和血管壁中积聚。 LAL 缺乏症是一种进行性疾病，具有多系统临床表现、严重的医疗併发症以及因肝功能衰竭而过早死亡，尤其是婴儿。

直到2015年，由于缺乏核准的治疗方法，全球LAL缺乏症治疗市场成长缓慢。药物治疗仅限于支持性护理，手术和他汀类药物等调脂药物仍是主要治疗。 2015 年，酵素替代疗法 (ERT) 经 Alexion Pharma 的 Kanuma（severipase alfa）核准进入 LAL-D 领域。 Kanuma 是一种特异性水解溶小体胆固醇酯和三酸甘油酯的酶，可静脉注射给 LAL 缺乏症患者。目前，Kanuma 是主要市场上唯一核准用于沃尔曼病（WD）和胆固醇酯贮积症（CESD）的药物。

根据治疗情况，支持性护理是 2017 年市场的主要收益来源。然而，在鹿沼的持续采用的支持下，ERT 产业预计将在预测期内实现最快的成长。由于大多数患者未被诊断或误诊，该疾病的预后仍然很差。因此，仍然强烈需要进行广泛的研究来了解疾病的生物学并开发旨在克服抗药性和最大限度地减少毒性的有效治疗方法。

溶小体酸性脂肪酶缺乏症治疗市场报告要点

  • CESD 发生在晚年，在白人和西班牙裔中更为常见，影响约三十万分之一的人。
  • 由于 ERT 类药物的高普及率和可用性，德国处于欧洲市场的前沿。
  • Kanuma 在 ERT 类别中的核准凸显了 LAL-D 缺乏症治疗方法的根本转变。
  • 由于 Kanuma 作为尚未开发的 LAL-D 患者群体中唯一的长期治疗药物的领先优势，预计 ERT 领域在预测期内将增长最快。
  • 由于同类别学名药的竞争加剧以及 Alexion 的 Kanuma 的采用增加，他汀类药物的市场占有率预计将下降。
  • 受 LAL 缺乏症影响的患者数量不断增加，且治疗性介入有限，这为投资该市场新治疗方法开发的公司提供了重大机会。
  • 由于预后不良和药物供应延迟而缺乏对疾病诊断的认识可能会抑制市场成长。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章溶小体酸性脂肪酶缺乏症治疗市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 营商环境分析
    • 产业分析-波特五力分析
    • PESTLE分析

第四章溶小体酸性脂肪酶缺乏症治疗市场：适应症业务分析

  • 指示市场占有率，2024/2030
  • 指示细分仪表板
  • 2018-2030 年市场规模/预测与趋势分析（依指标）
  • 沃尔曼病 (WD)
  • 胆固醇酯贮积症（CESD）

第五章溶小体酸性脂肪酶缺乏症治疗市场：治疗业务分析

  • 2024年及2030年治疗市场占有率
  • 治疗细分仪表板
  • 2018-2030 年市场规模/预测与趋势分析（按处理方式）
  • 酵素替代疗法（ERT）
  • 支持性护理
  • 脂质改质剂
  • 其他的

第六章溶小体酸性脂肪酶缺乏症治疗市场：区域估计与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
    • 按国家/地区划分，2018-2030
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 按国家/地区划分，2018-2030
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 丹麦
    • 瑞典
  • 亚太地区
    • 按国家/地区划分，2018-2030
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 按国家/地区划分，2018-2030
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 按国家/地区划分，2018-2030
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争格局

  • 参会企业概况
  • 公司市场分析
  • 公司分类
  • 策略规划
  • 公司简介/名单
    • Alexion Pharmaceuticals, Inc.（AstraZeneca）
    • Amgen Inc.
    • BioCrick BioTech
    • Lupin
    • Merck KGaA
    • Pfizer Inc.
    • Regeneron Pharmaceuticals Inc.
    • Teva Pharmaceutical Industries Ltd
Product Code: GVR-2-68038-610-3

Lysosomal Acid Lipase Deficiency Treatment Market Growth & Trends:

The global lysosomal acid lipase deficiency treatment market size is expected to reach USD 433.2 million by 2030, registering a CAGR of 7.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. High unmet needs, rising prevalence, and increasing uptake of enzyme replacement therapy are some of the primary factors driving the market.

LAL deficiency (LAL-D) is a rare type of lysosomal storage disorder in which patients are unable to breakdown cholesteryl esters and triglycerides due to a mutation in the LAL gene. As a result, there is an accumulation of lipids in the liver, spleen, and walls of blood vessels. LAL deficiency is a progressive disease with multi-systemic clinical manifestations, significant medical complications, and early mortality due to liver failure, especially among infants.

Until 2015, the global LAL deficiency treatment market witnessed modest growth due to a lack of approved treatments for the disease. Medical care was limited to supportive care, with surgery and lipid-modifying drugs such as statins remained the mainstay for treatment. In 2015, approval of Alexion Pharma's Kanuma (sebelipase alfa) marked the entry of enzyme replacement therapy (ERT) in the LAL-D space. Kanuma is a hydrolytic lysosomal cholesterol ester and triacylglycerol specific enzyme, administered intravenously in patients with LAL deficiency. Currently, Kanuma is the only drug approved for both Wolman disease (WD) and Cholesteryl Ester Storage Disease (CESD) in the key markets.

Based on treatment, supportive care was the leading revenue contributor in the market in 2017. However, the ERT segment is expected to register the fastest growth during the forecast period, supported by continued uptake of Kanuma. Disease prognosis remains poor, as a majority of patients are either undiagnosed or misdiagnosed. Thus, there remains a strong need for extensive research to understand disease biology and develop effective therapeutic options with the goal to overcome resistance and minimize toxicity.

Lysosomal Acid Lipase Deficiency Treatment Market Report Highlights:

  • CESD manifests later in life and is more prevalent among Caucasians and Hispanic populations, affecting approximately 1 in 300,000 individuals.
  • Germany is at the forefront of the Europe market and is driven by high disease prevalence and availability of drugs in the ERT class.
  • Approval of Kanuma in ERT class highlight a fundamental shift in treatment approach to LAL-D deficiency.
  • The ERT segment is estimated to be the fastest-growing during the forecast period, owing to Kanuma's first-mover advantage as the only long-term treatment in untapped LAL-D patient population pool.
  • Statins are anticipated to lose market share due to rising competition from generics within the class and increasing uptake of Alexion's Kanuma.
  • Rising eligible patient population and limited therapeutic intervention for LAL deficiency offer a strong commercial opportunity for players to invest in developing novel treatments in this market.
  • Lack of awareness in disease diagnosis and delayed access to medications due to poor prognosis may restrain the growth of the market.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Treatment
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Lysosomal Acid Lipase Deficiency Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Lysosomal Acid Lipase Deficiency Treatment Market: Indication Business Analysis

  • 4.1. Indication Market Share, 2024 & 2030
  • 4.2. Indication Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 4.4. Wolman Disease (WD)
    • 4.4.1. Wolman Disease (WD) Market, 2018 - 2030 (USD Million)
  • 4.5. Cholesteryl Ester Storage Disease (CESD)
    • 4.5.1. Cholesteryl Ester Storage Disease (CESD) Market, 2018 - 2030 (USD Million)

Chapter 5. Lysosomal Acid Lipase Deficiency Treatment Market: Treatment Business Analysis

  • 5.1. Treatment Market Share, 2024 & 2030
  • 5.2. Treatment Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
  • 5.4. Enzyme Replacement Therapy (ERT)
    • 5.4.1. Enzyme Replacement Therapy (ERT) Market, 2018 - 2030 (USD Million)
  • 5.5. Supportive Care
    • 5.5.1. Supportive Care Market, 2018 - 2030 (USD Million)
  • 5.6. Lipid Modifying Agents
    • 5.6.1. Lipid Modifying Agents Market, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Lysosomal Acid Lipase Deficiency Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Norway
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Norway Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Denmark
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Denmark Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Sweden
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Sweden Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. South Korea Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Australia Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Alexion Pharmaceuticals, Inc. (AstraZeneca)
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Amgen Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. BioCrick BioTech
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Lupin
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Merck KGaA
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Pfizer Inc.
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Regeneron Pharmaceuticals Inc.
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Teva Pharmaceutical Industries Ltd
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global lysosomal acid lipase deficiency treatment market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 5 Global lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 6 North America lysosomal acid lipase deficiency treatment market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 8 North America lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 9 U.S lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 10 U.S Lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 11 Canada lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 12 Canada lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 13 Mexico lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 14 Mexico lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 15 Europe lysosomal acid lipase deficiency treatment market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 17 Europe lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 18 UK lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 19 UK Lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 20 Germany lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 21 Germany lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 22 France lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 23 France Lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 24 Italy lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 25 Italy lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 26 Spain lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 27 Spain lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 28 Norway lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 29 Norway Lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 30 Denmark lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 31 Denmark lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 32 Sweden lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 33 Sweden lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific lysosomal acid lipase deficiency treatment market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 37 Japan lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 38 Japan lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 39 China lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 40 China lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 41 India lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 42 India lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 43 Australia lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 44 Australia lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 45 South Korea lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 46 South Korea lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 47 Thailand lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 48 Thailand lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 49 Latin America lysosomal acid lipase deficiency treatment market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 51 Latin America lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 52 Brazil lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 53 Brazil lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 54 Argentina lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 55 Argentina lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Lysosomal acid lipase deficiency treatment market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 59 South Africa lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 60 South Africa lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 63 UAE lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 64 UAE lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 65 Kuwait lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 66 Kuwait lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Lysosomal acid lipase deficiency treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Indication and treatment outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Lysosomal acid lipase deficiency treatment market dynamics
  • Fig. 12 Lysosomal acid lipase deficiency treatment market: Porter's five forces analysis
  • Fig. 13 Lysosomal acid lipase deficiency treatment market: PESTLE analysis
  • Fig. 14 Lysosomal acid lipase deficiency treatment market: Indication segment dashboard
  • Fig. 15 Lysosomal acid lipase deficiency treatment market: Indication market share analysis, 2024 & 2030
  • Fig. 16 Wolman disease (WD) market, 2018 - 2030 (USD Million)
  • Fig. 17 Cholesteryl ester storage disease (CESD) market, 2018 - 2030 (USD Million)
  • Fig. 18 Lysosomal acid lipase deficiency treatment market: Treatment segment dashboard
  • Fig. 19 Lysosomal acid lipase deficiency treatment market: Treatment market share analysis, 2024 & 2030
  • Fig. 20 Enzyme replacement therapy (ERT) market, 2018 - 2030 (USD Million)
  • Fig. 21 Supportive care market, 2018 - 2030 (USD Million)
  • Fig. 22 Lipid modifying agents market, 2018 - 2030 (USD Million)
  • Fig. 23 Others market, 2018 - 2030 (USD Million)
  • Fig. 24 Lysosomal acid lipase deficiency treatment market revenue, by region
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 Regional marketplace: Key takeaways
  • Fig. 27 North America lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. country dynamics
  • Fig. 29 U.S. lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 30 Canada country dynamics
  • Fig. 31 Canada lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 32 Mexico country dynamics
  • Fig. 33 Mexico lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 34 Europe lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 35 UK country dynamics
  • Fig. 36 UK lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 37 Germany country dynamics
  • Fig. 38 Germany lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 39 France country dynamics
  • Fig. 40 France lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 41 Italy country dynamics
  • Fig. 42 Italy lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain country dynamics
  • Fig. 44 Spain lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 45 Norway country dynamics
  • Fig. 46 Norway lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 47 Sweden country dynamics
  • Fig. 48 Sweden lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 49 Denmark country dynamics
  • Fig. 50 Denmark lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Japan country dynamics
  • Fig. 53 Japan lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 54 China country dynamics
  • Fig. 55 China lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 56 India country dynamics
  • Fig. 57 India lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 58 Australia country dynamics
  • Fig. 59 Australia lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 60 South Korea country dynamics
  • Fig. 61 South Korea lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 62 Thailand country dynamics
  • Fig. 63 Thailand lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 64 Latin America lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 65 Brazil country dynamics
  • Fig. 66 Brazil lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 67 Argentina country dynamics
  • Fig. 68 Argentina lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 69 MEA lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 70 South Africa country dynamics
  • Fig. 71 South Africa lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 72 Saudi Arabia country dynamics
  • Fig. 73 Saudi Arabia lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 74 UAE country dynamics
  • Fig. 75 UAE lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 76 Kuwait country dynamics
  • Fig. 77 Kuwait lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 78 Company categorization
  • Fig. 79 Company market position analysis
  • Fig. 80 Strategic framework